Abstract
Get full access to this article
View all access options for this article.
References
1.
Burrill SB
: Biotechnology product pricing: Issues, concerns and strategies . Biopharm
2 :12 -18 ,1989
2.
Herfindal ET
: Formulary management of biotechnological drugs . Am J Hosp Pharm
46 :2516 -1520 ,1989
3.
Detsky AS
,
Naglie G.
: A clinician's guide to cost-effectiveness analysis . Ann Intern Med
113 :147 -154 , 1990
4.
Finley RS
: Measuring the cost effectiveness of hematopoietic growth factor therapy . Cancer
1991 (in press)
5.Medicare Carriers Manual (Part 3: Claims Process). Coverage and Limitations. HCFA-Pub 14-3, Transmittal No. 1204 , August, 1987 , pp 2 -15
6.
Huber SL
: Reimbursement issues with interferon therapies . Semin Oncol
15 :54 -57 , 1988 (suppl 5 )
7.
Anon
: Use of approved drugs for unlabeled indicators . FDA Drug Bulletin
12 :4 -5 ,1982
8.
Koda RT
: Curriculum for pharmacy practice: A perspective from the pharmaceutical sciences . J Pharm Pract
3 :85 -90 , 1990